# US 2022/0370434 A1 · Methods and compositions for treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0370434 A1
- Document ID: US20220370434A1
- Status: Published application
- Kind: A1
- Application number: 17/627,059
- Filed: 2020-07-23
- Published: 2022-11-24
- Earliest claimed: 2019-07-23
- Assignees: City of Hope
- Applicants: City of Hope
- Inventors: Jianjun Chen; Rui Su; David Horne; Xiaolan Deng; Hongzhi Li; Jun Xie
- Web page: https://patentgrep.com/patent/US20220370434A1

## CPC

- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61K 31/473: ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/497: containing further heterocyclic rings
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/706: containing six-membered rings with nitrogen as a ring hetero atom
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07D 215/52: with aryl radicals attached in position 2
- C07D 219/04: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C07D 233/52: with hetero atoms directly attached to said nitrogen atoms
- C07D 233/88: Nitrogen atoms, e.g. allantoin
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 403/14: containing three or more hetero rings
- G01N 33/573: for enzymes or isoenzymes
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided, inter alia, are methods and compositions for treating FTO-mediated cancer.

## Claims

### Claim 1

A method of treating cancer in a subject in need thereof, the method comprising administering a therapeutically effective amount of an FTO inhibitor, wherein the subject has an elevated level of FTO when compared to a control, and wherein the FTO inhibitor has the structural formula I or II,
or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.

### Claim 2

(canceled)

### Claim 3 (depends on 2)

The method of claim 2, further comprising measuring an FTO level in a biological sample obtained from the subject.

### Claim 4 (depends on 3)

The method of claim 3, wherein the biological sample is a tumor sample.

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7 (depends on 3)

The method of claim 3, wherein the biological sample is a normal tissue sample, wherein the normal tissue sample is a bone marrow, brain, breast, lung, pancreatic, kidney, prostate, liver, or colon tissue sample.

### Claim 8

(canceled)

### Claim 9 (depends on 3)

The method of claim 3, wherein the blood sample is a peripheral blood sample.

### Claim 10 (depends on 2)

The method of claim 2, wherein the FTO inhibitor has the formula Ia, Ib or IIa:
or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, wherein:
R1 and R2 are independently hydrogen, halogen, —CCl3, —CBr3, —CF3, —CI3, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CHCl2, —CHBr2, —CHF2, —CHI2, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCBr3, —OCF3, —OCI3, —OCH2Cl, —OCH2Br, —OCH2F, —OCH2I, —OCHCl2, —OCHBr2, —OCHF2, —OCHI2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein at least one of R1 or R2 is not hydrogen.

### Claim 11

A compound of formula Ia, Ib, (IIa) or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof:
wherein
R1 and R2 are independently hydrogen, halogen, —CCl3, —CBr3, —CF3, —CI3, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CHCl2, —CHBr2, —CHF2, —CHI2, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —SO4H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCBr3, —OCF3, —OCI3, —OCH2Cl, —OCH2Br, —OCH2F, —OCH2I, —OCHCl2, —OCHBr2, —OCHF2, —OCHI2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein at least one of R1 or R2 is not hydrogen.

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14 (depends on 11)

The compound of claim 11, wherein R1 and R2 are independently methyl, ethyl, propyl, butyl, or pentyl.

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17 (depends on 1)

The method of claim 1, wherein the cancer is leukemia, myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), myeloma, lymphoma, brain tumor, breast cancer, lung cancer, pancreatic cancer, kidney cancer, prostate cancer, liver cancer, glioblastoma (GBM), lung squamous cell carcinoma (LUSC), or colon cancer.

### Claim 18

(canceled)

### Claim 19 (depends on 17)

The method of claim 17, wherein leukemia is acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), or chronic lymphocytic leukemia (CLL).

### Claim 20

(canceled)

### Claim 21 (depends on 11)

A pharmaceutical composition for treating cancer, wherein the pharmaceutical composition comprises the compound of claim 11, and a pharmaceutically acceptable excipient, wherein the cancer is a cancer modulated by an FTO inhibitor.

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25 (depends on 21)

The pharmaceutical composition of claim 21, wherein the leukemia is acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), or chronic lymphocytic leukemia (CLL).

### Claim 26

(canceled)

### Claim 27 (depends on 21)

The pharmaceutical composition of claim 21, further comprising one or more additional anti-cancer agents.

### Claim 28

A method of measuring FTO levels in a subject, the method comprising: (i) obtaining a biological sample from the subject; and (ii) measuring FTO levels in the biological sample; wherein if the FTO level is elevated when compared to a control, the subject is identified as responsive to the FTO inhibitor and wherein if the FTO level is elevated when compared to a control, the subject is selected for treatment with the FTO inhibitor.

### Claim 29

(canceled)

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32

(canceled)

### Claim 33 (depends on 28)

The method of claim 28, wherein the biological sample is a normal tissue sample, wherein the normal tissue is a bone marrow, brain, breast, lung, pancreatic, kidney, prostate, liver, or colon tissue sample, wherein the biological sample is a peripheral blood sample.

### Claim 34

(canceled)

### Claim 35

(canceled)

### Claim 36 (depends on 1)

The method of claim 1, further comprising administering of a therapeutically effective amount of one or more additional anti-cancer agents.

### Claim 37 (depends on 36)

The method of claim 36, wherein the additional anti-cancer agent is selected from the group consisting of cytarabine, anthracycline, temozolomide, a hypomethylating agent (HMA), a tyrosine kinase inhibitor (TKI), an FLT3 inhibitor, an isocitrate dehydrogenase inhibitor (IDH), and a MYC inhibitor.

### Claim 38

(canceled)

### Claim 39

A method of measuring FTO levels in a subject wherein the subject has cancer, the method comprising: (i) obtaining a biological sample from the subject; and (ii) measuring FTO levels in the biological sample.

### Claim 40

(canceled)

### Claim 41

(canceled)

### Claim 42

(canceled)

### Claim 43 (depends on 39)

The method of claim 39, wherein the biological sample is a blood sample.

### Claim 44

(canceled)

### Claim 45

A method of treating cancer in a subject in need thereof, the method comprising: (i) obtaining a biological sample from the subject; and (ii) measuring FTO levels in the biological sample; and (iii) administering a therapeutically effective amount of an FTO inhibitor.

### Claim 46 (depends on 45)

The method of claim 45, wherein the cancer is leukemia, myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), myeloma, lymphoma, brain tumor, breast cancer, lung cancer, pancreatic cancer, kidney cancer, prostate cancer, liver cancer, glioblastoma (GBM), lung squamous cell carcinoma (LUSC), or colon cancer.

### Claim 47

(canceled)

### Claim 48 (depends on 46)

The method of claim 46, wherein the leukemia is acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), or chronic lymphocytic leukemia (CLL).

### Claim 49

(canceled)

### Claim 50

(canceled)

### Claim 51

(canceled)

### Claim 52

(canceled)

### Claim 53

(canceled)

### Claim 54

(canceled)

### Claim 55

A method of preparing a sample from a subject having cancer, the method comprising:
(i) extracting a protein fraction or an RNA fraction from a sample from said subject; and
(ii) detecting a level of FTO protein in said protein fraction or a level of FTO encoding RNA in said RNA fraction.

### Claim 56

(canceled)

### Claim 57

(canceled)

### Claim 58

(canceled)

### Claim 59

(canceled)

### Claim 60 (depends on 55)

The method of claim 55 comprising detecting the level of FTO protein in said protein fraction or a level of FTO encoding RNA in said RNA fraction further comprising the steps of:
a) labeling human primary cells with CD34 surface marker;
b) washing the cells with chilled phosphate-buffered saline;
c) re-suspending the cells in 4% paraformaldehyde at a density of 2×106 cells/ml;
d) incubating the cells at 4° C. for 20 min with rotation;
e) re-suspending the cells in 5× Permeabilization buffer;
f) staining the cells with anti-FTO (1:100) for one hour;
g) washing the cells twice with 1× Permeabilization buffer;
h) incubating the cells with an anti-rabbit IgG in 5× Permeabilization buffer for 30 min at room temperature; and
i) storing the cells in FACS buffer for FTO analysis.

### Claim 61

(canceled)

### Claim 62

(canceled)

### Claim 63

(canceled)

### Claim 64

(canceled)
